Research programme: glucocorticoid receptor modulators - Ligand

Drug Profile

Research programme: glucocorticoid receptor modulators - Ligand

Alternative Names: LGD 5552

Latest Information Update: 06 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Glucocorticoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Inflammation

Most Recent Events

  • 16 Mar 2007 Ligand Pharmaceuticals discontinues development of LGD 5552, but will continue to develop other potential drug candidates
  • 01 Jul 2005 Data presented at the 87th Annual Meeting of the Endocrine Society (ENDO-2005) have been added to the Inflammatory disorders pharmacodynamics section
  • 28 Jun 2004 Data presented at the 86th Annual Meeting of the Endocrine Society (ENS-2004) have been added to the Neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top